A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Author: Ko Andrew   Venook Alan   Bergsland Emily   Kelley R.   Korn W.   Dito Elizabeth   Schillinger Brian   Scott Janet   Hwang Jimmy   Tempero Margaret  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.66, Iss.6, 2010-11, pp. : 1051-1057

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content